offer
all report title image
  • Published On : Nov 2022
  • Code : CMI173
  • Industry : Pharmaceutical
  • Pages : 169
  • Formats :

The global PD-1 and PD-L1 inhibitor market was valued at US$ 30,535.5 Mn in 2021 and is forecast to reach a value of US$ 77,541.1 Mn by 2028 at a CAGR of 14.2% between 2022 and 2028. The global PD-1 and PD-L1 inhibitor market is experiencing strong growth due to the rise in incidence or prevalence of cancer and growing geriatric population around the world. Moreover, increase in awareness among people about immune checkpoint inhibitors is expected to boost the growth of the market. However, high cost of cancer treatment and risk of complications associated with the treatment is expected to hamper growth of the global PD-1 and PD-L1 inhibitor market.

Global PD-1 and PD-L1 Inhibitor Market: Regional Insights

Based on geography, the PD-1 and PD-L1 inhibitor market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period owing to the increasing prevalence of cancer and favourable initiatives by the regulatory authorities in the region, especially in the United States. For instance, PD-1 and PD-L1 inhibitors are vital immune checkpoint inhibitors used to treat variety of cancer. According to the American Cancer Society, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. This in turn is expected to increase demand for PD-1 and PD-L1 inhibitors in the region.

Asia Pacific is also expected to witness significant growth in the global PD-1 and PD-L1 inhibitor market owing to the high prevalence of cancer together with growing geriatric population in this region, especially in India. For instance, according to the cancer report by the Indian Council of Medical Research (ICMR), India’s cancer cases could increase by 12% in the next five years, with 1.5 million people projected to suffer from the non-communicable disease by 2025, up from 1.39 million in 2020. This in turn is expected to increase demand for PD-1 and PD-L1 inhibitors.

Figure 1. Global PD-1 and PD-L1 Inhibitor Market Share (%), by Region, 2021

PD-1 and PD-L1 Inhibitor  | Coherent Market Insights

Global PD-1 and PD-L1 Inhibitor Market Drivers:

Rise in incidence/prevalence of cancer across the globe is expected to boost growth of the global PD-1 and PD-L1 inhibitor market during the forecast period. For instance, PD-1/PD-L1 inhibitors are important immune checkpoint inhibitors (ICIs) used as front-line treatments for several types of cancer. According to the World Health Organization (WHO), cancer was one of the leading cause of death worldwide, accounting for around ten million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. Thus, there is an increase in demand for PD-1 and PD-L1 inhibitors worldwide.

Growing geriatric population around the world is expected to augment growth of the global PD-1 and PD-L1 inhibitor market during the forecast period. For instance, according to the Union for International Cancer Control (UICC), elderly (people aged 65 years and more) are 11 times more likely to develop cancer, compared to younger people. According to the United Nations, there are over 703 million people aged 65 or older, a number that is projected to reach 1.5 billion by 2050. According to the latest estimates and projections from UN DESA’s Population Division, one in six people in the world will be over the age 65 by 2050, up from 1 in 11 in 2019.

CMI table icon

PD-1 and PD-L1 Inhibitor Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 30,535.5 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 14.2% 2028 Value Projection: US$ 77,541.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type of Inhibitor: PD-1 Inhibitors and PD-L1 Inhibitors
  • By Application: Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, and Others
  • By End Users: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Companies covered:

Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc.

Growth Drivers:
  • Rise in incidence/prevalence of cancer worldwide
  • Growing geriatric population around the world
Restraints & Challenges:
  • High cost of cancer treatment
  • Risk of complications associated with the treatment

Global PD-1 and PD-L1 Inhibitor Market Opportunities:

Rise in research and development activities are expected to offer significant growth opportunities for players in the PD-1 and PD-L1 inhibitor market. For instance, market players are increasingly investing in research and development activities to meet the increasing demand. Researchers at Johns Hopkins Kimmel Cancer Center are leading the way in developing novel immunotherapies called anti-PD-1 and anti-PD-L1 for people with advanced melanomas. The aim of the therapy is not to kill cancer cells directly, but to block a pathway that protects tumor cells from components of the immune system that are capable and ready to fight cancer.

Increase in awareness among people about immune checkpoint inhibitors is expected to provide significant growth opportunities for players in the global PD-1 and PD-L1 inhibitor market. For instance, with the increase in awareness among people, the demand for PD-1 and PD-L1 inhibitors is also increasing with a rapid pace worldwide. To date, the Food and Drug Administration (FDA) has approved seven immune checkpoint inhibitors for the PD1/PDL1 pathway: four anti-PD1 and three anti-PDL1 mAbs, including the anti-PD1 mAb dostarlimab, approved in April 2021.

Global PD-1 and PD-L1 Inhibitor Market Trends:

Growing burden of cancer around the world has increased or increasing the use of PD-1 and PD-L1 inhibitors as PD-1 and PD-L1 inhibitors are important immune checkpoint inhibitors used as front-line treatments for several types of cancer. Thus, with the increase in increase in prevalence of cancer, the use of PD-1/PD-L1 inhibitors is also increasing. This trend is expected to continue during the forecast period, driving the growth of the market.

Moreover, there is an increase in demand for pembrolizumab (KEYTRUDA) across the globe due to its proven efficiency to treat many FDA-Approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), and melanoma. Thus, players in the market are investing huge for the development of these products, and this trend is expected to continue over the forecast period, driving the growth of the market.

Global PD-1 and PD-L1 Inhibitor Market Restraints:

High cost of cancer treatment is expected to hamper growth of the global PD-1 and PD-L1 inhibitor market. For instance, on average, the cost of cancer treatment in India is around INR 503,118 (US$ 6,300) with a minimum expense of INR 90,561 (US$ 1,134) and maximum cost of INR 27,67,149 (USD 34,650). Moreover, the cost of available PD-1 and PD-L1 inhibitors is high, however, the cost of cancer treatment depends on the stage of the cancer.

Risk of complications associated with the treatment is expected to hinder growth of the global PD-1 and PD-L1 inhibitor market. For instance, cancer treatment can cause many side effects, such as depression, trouble eating, and tiredness. The National Cancer Institute and the American Cancer Society describe many of these problems and offer tips for preventing or coping with them. Several side effects can happen months or years after treatment.

Figure 2. Global PD-1 and PD-L1 Inhibitor Market Share (%), by Type of Inhibitors, 2021

PD-1 and PD-L1 Inhibitor  | Coherent Market Insights

Global PD-1 and PD-L1 Inhibitor Market Segmentation:

The global PD-1 and PD-L1 inhibitor market report is segmented into Type of Inhibitor, Application, End Users, and Geography.

Based on Type of Inhibitor, the market is segmented into PD-1 Inhibitors and PD-L1 Inhibitors. Out of which, PD-1 Inhibitors Segment is expected to dominate the PD-1 and PD-L1 inhibitor market over the forecast period and this is attributed to the rise in burden of cancer worldwide. Its major role has been identified in inhibiting the immune responses to tumors.

Based on Application, the global PD-1 and PD-L1 inhibitor market is segmented into Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, and Others. Out of which, Hodgkin Lymphoma Segment is expected to dominate the market over the forecast period and this is attributed to the rise in research and development. PD-1/PD-L1 pathway and PD-1 inhibitors have been widely tested in patients with a variety of lymphomas.

Kidney Cancer Segment is also expected to witness significant growth in the near future and this is owing to the increase in prevalence of kidney cancer. PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors used to treat variety of cancer, such as kidney cancer.

Based on End Users, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, Hospital Pharmacies Segment is expected to dominate the market over the forecast period and this is attributed to the rise in demand for safe and effective cancer treatment. Required oncology drugs are available in hospital pharmacies at the earliest.

Online Pharmacies Segment is also expected to witness significant growth in the near future and this is owing to the increase in preference for online pharmacies or increase in popularity of online pharmacies as they offer huge discounts on medications. Moreover, nowadays, people avoid going to crowded places and hence are ordering their medications online.

Global PD-1 and PD-L1 Inhibitor Market: Key Developments

In May 2020, the Food and Drug Administration (FDA) approved Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung.

In Jnauary 2020, Merck & Co. acquired ArQule Inc., a company that develops therapeutics based on its proprietary Activated Checkpoint Therapy platform.

In July 2019, Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the United States.

Global PD-1 and PD-L1 Inhibitor Market: Key Companies Insights

The global PD-1 and PD-L1 inhibitor market is highly competitive. This is attributed to the rise in burden of cancer and growing geriatric population, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global PD-1 and PD-L1 inhibitor market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc.

*Definition: PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors used as a front-line treatment for several types of cancer, such as Hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, and others. PD-1/PD-L1 inhibitors are drugs that help the body recognize and attack cancer cells.

PD-1 and PD-L1 inhibitors are important immune checkpoint inhibitors (ICIs) used as a front-line treatment for several types of cancer. These inhibitors are often used to treat Hodgkin lymphoma, kidney cancer, melanoma, and non-small cell lung cancer, among others. PD-1/PD-L1 inhibitors are drugs that help the body recognize and attack cancer cells. Thus, there is an increase in demand for PD-1 and PD-L1 inhibitors across the globe.

Market Dynamics:

Increase in prevalence of cancer, growing geriatric population, rise in awareness about immune checkpoint inhibitors, increase in focus on the development of safe and effective cancer treatment, and favorable government initiatives are major factors expected to propel growth of the global PD-1 and PD-L1 inhibitor market over the forecast period.

For instance, in October 2021, Merck received the U.S. Food and Drug Administration (USFDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test.

Key features of the study:

  • This report provides in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Novartis, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.

Detailed Segmentation:

  • Global PD-1 and PD-L1 Inhibitor Market By Type of Inhibitor:
    • PD-1 Inhibitors
    • PD-L1 Inhibitors
  • Global PD-1 and PD-L1 Inhibitor Market By Application:
    • Hodgkin Lymphoma
    • Kidney Cancer
    • Melanoma
    • Non-small Cell Lung Cancer
    • Others
  • Global PD-1 and PD-L1 Inhibitor Market By End Users:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global PD-1 and PD-L1 Inhibitor Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG
    • AstraZeneca PLC
    • Gilead Sciences Inc.
    • Amgen Inc.
    • Sanofi AG
    • Hoffmann-La Roche AG
    • Merck & Co.
    • Bristol-Myers Squibb Company
    • Regeneron Pharmaceuticals Inc.

Frequently Asked Questions

The global PD-1 and PD-L1 inhibitor market size is estimated to be valued at US$ 34,865.4 Million in 2022 and is expected to exhibit a CAGR of 14.2% between 2022 and 2028.
Rise in incidence/prevalence of cancer and growing geriatric population worldwide is fueling the market.
PD-1 Inhibitors segment is the leading type of inhibitors segment in the market.
High cost of cancer treatment and risk of complications associated with the treatment are major factors restraining growth of the market.
Major players operating in the market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, and Regeneron Pharmaceuticals Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo